The rs4783961 and rs708272 genetic variants of the CETP gene are associated with coronary artery disease, but not with restenosis after coronary stenting

Los polimorfismos rs4783961 y rs708272 del gen CETP son asociados con la enfermedad arterial coronaria y no con la restenosis tras el implante de un stent coronario

Gilberto Vargas-Alarcón, Oscar Pérez-Méndez, Rosalinda Posadas-Sánchez, Marco A. Peña-Duque, Marco A. Martínez-Ríos, Hilda Delgadillo-Rodríguez, and José M. Fragoso*

1Department of Molecular Biology; 2Department of Endocrinology; 3Interventional Cardiology. Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

Abstract

Objective: We evaluated whether cholesteryl ester transfer protein (CETP) gene polymorphisms are associated with the presence of coronary artery disease (CAD) and/or restenosis in patients with coronary stent. Methods: Two polymorphisms of the CETP gene [−971 A/G (rs4783961), and Taq1B A/G (rs708272)] were genotyped by 5’ exonuclease TaqMan assays in 219 patients with CAD (66 patients with restenosis and 153 without restenosis) and 607 control individuals. Results: The distribution of polymorphisms was similar in patients with and without restenosis. However, when the whole group of patients (with and without restenosis) was compared to healthy controls, under dominant model, the G allele of the Taq1B A/G polymorphism was associated with increased risk of CAD (odds ratio [OR] = 1.48, pC_Dom = 0.032). In the same way, under codominant, dominant, and additive models, the A allele of the −971 A/G polymorphisms was associated with an increased risk of developing CAD (OR = 2.03, pC_Co-dom = 0.022, OR = 1.83, pC_Dom = 0.008, and OR = 1.39, pC_Add = 0.011, respectively). In addition, the linkage disequilibrium showed that the “AG” haplotype was associated with increased risk of developing CAD (OR = 1.28, p = 0.03). Conclusion: This study demonstrates that CETP Taq1B A/G and CETP −971 A/G polymorphisms are associated with an increased risk of developing CAD, but no association with restenosis was observed.

Keywords: Genetics. High-density lipoprotein cholesterol. Coronary artery disease.

Resumen

Objetivo: Evaluamos si los polimorfismos del gen CETP están asociados con la presencia de enfermedad arterial coronaria (EAC) y/o restenosis en pacientes con stent coronario. Métodos: En este estudio se genotiparon dos polimorfismos del gen CETP [−971 A/G (rs4783961) y Taq1B A/G (rs708272)] mediante ensayos de 5’exonucleasa TaqMan en 219 pacientes con EAC (66 pacientes con restenosis y 153 sin restenosis), y 607 individuos de control. Resultados: La distribución de polimorfismos fue similar en pacientes con y sin restenosis. Sin embargo, cuando se comparó todo el grupo de pacientes (con y sin restenosis) con controles sanos, bajo el modelo dominante el alelo G del polimorfismo Taq1B A/G se asoció con un
mayor riesgo de EAC (OR = 1.48, pC_{Dom} = 0.032). De la misma manera, bajo los modelos co-dominante, dominante y aditivo, el alelo A de los polimorfismos −971 A/G se asocia con un mayor riesgo de desarrollar EAC (OR = 2.03, pC_{Co-dom} = 0.022, pC_{Dom} = 0.008 y OR = 1.39, pC_{Add} = 0.011, respectivamente). Adicionalmente, el desequilibrio de ligamiento mostró que el haplótipo “AG” se asocia con un mayor riesgo de desarrollar EAC (OR = 1.28, p = 0.03). Conclusión: En resumen, este estudio demuestra que los polimorfismos CETP Taq1B A/G y CETP −971 A/G están asociados con un mayor riesgo de desarrollar CAD, pero no se observó asociación con restenosis.

Palabras clave: Genética. Colesterol lipoproteínas de alta densidad. Enfermedad arterial coronaria.

Introduction

Coronary artery disease (CAD) is a complex, multifactorial disease, influenced by pathophysiologic conditions as well as by genetic and environmental factors. Currently, the treatment strategy for this disease is the intracoronary stent. However, data in the literature has shown that after intracoronary stent placement between 12 to 32% of the patients develop restenosis\(^4\). The restenosis is the arterial wall’s healing response to mechanical injury and comprises two main processes, one is the neointimal hyperplasia that involves the smooth muscle migration/proliferation, extracellular matrix deposition, and vessel remodeling and the other is the vessel remodeling\(^2,4\).

Data in the literature, it has been suggested that the higher concentration of high-density lipoprotein (HDL) cholesterol has an important role anti-atherogenic in the development of the atherosclerotic plaque\(^5-7\). In addition, the evidences indicate that the risk of restenosis following a vascular intervention is inversely related to HDL cholesterol (HDL-C)\(^8-10\). Cholesteryl ester transfer protein (CETP) is an exchange protein, transporting cholesterol from HDL particles to apoB-containing lipoproteins (low-density lipoproteins [LDL] and very LDL) to replace it with triglycerides\(^5-7\). Nonetheless, changes in activity and concentrations of this protein impair reverse cholesterol transport and promote the atherosclerotic process\(^11\), strongly suggesting that this protein may be an important pro-restenotic factor.

The CETP protein is encoded by CETP gene, which is located in chromosome 16q23-24. In addition, several studies have been associated two single-nucleotide polymorphisms (SNPs) in the CETP gene, one in the promoter region [position −971 A/G (rs4783961)] and other in intron 1 named Taq1B [position A5454-G (rs708272)], with an increased activity of CETP protein\(^12\), and with risk of developing CAD, myocardial infarction, and dyslipidemia\(^2,16\).

Considering the prominent role of this gene in the concentrations and remodeling of HDL-C, the aim of the study was to establish the role of the CETP −971 A/G and CETP Taq1B A/G polymorphisms in the susceptibility to developing restenosis after coronary stent placement in the Mexican population.

Materials and Methods

Study population

This case–control study was carried out in the Instituto Nacional de Cardiología Ignacio Chavez. The sample size was calculated for matched cases and controls with OpenEpi software (http://www.openepi.com/SampleSize/SSCC.html). The study included 826 Mexican Mestizos individuals (219 patients with CAD and 607 healthy controls matched by age and gender). The patients with CAD were underwent coronary stent implantation at our institution during the period between October 2008 and October 2014. After 6 months went to follow-up, coronary angiography because of symptoms of ischemia documented in a myocardial perfusion imaging test. Basal and procedure coronary angiographies were analyzed for angiographic predictors of restenosis, and follow-up angiography was performed to screen for binary restenosis. Using a >50% stenosis at follow-up (50% reduction in the luminal diameter of the stenosis compared with the coronary angiography findings immediately following angioplasty) as the criterion to define restenosis, there were 66 patients with restenosis (30%) and 153 without restenosis (70%). Moreover, we included 607 healthy controls without a family history of CAD with negative calcium score, indicative of absence of subclinical atherosclerosis coming from the Genetics of Atherosclerosis Disease Mexican study previously described by Rosalinda-Posadas et al.\(^17\). The exclusion criteria included the use antidiyslipidemic, antihypertensive, and antidiabetic drugs at the time of the study. Both groups (patients with CAD and healthy controls) were considered Mexican mestizos and ethnically matched according to ancestry informative markers using the ADMIXTURE software. This study was conducted according to the
Laboratory analysis

Cholesterol and triglycerides plasma concentrations were determined by enzymatic/colorimetric assays (Randox Laboratories, UK). HDL-C concentrations were determined after precipitation of the apoB-containing lipoproteins by the method of the phosphotungstic acid-Mg\(^{2+}\). The LDL-C concentration was determined in samples with a triglyceride level lower than 400 mg/dl with the Friedewald formula\(^{18}\). Dyslipidemia was defined as the presence of one or more of the following conditions: cholesterol > 200 mg/dl, LDL-C > 130 mg/dl, HDL-C < 40 mg/dl, or triglycerides > 150 mg/dl, according to the guidelines of the National Cholesterol Education Project Adult Treatment Panel (ATP III) (http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm). Type 2 diabetes mellitus (T2DM) was defined with a fasting glucose ≥ 126 mg/dL; it was also considered when participants reported glucose-lowering treatment or a physician diagnosis of T2DM. Hypertension was defined by a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the use of oral anti-hypertensive therapy\(^{17}\).

Functional prediction analysis

Two in silico programs and SNP function prediction were used to predict the possible functional effect of CETP gene polymorphisms. Both programs (ESE-finder 2.0 and SNPinfo) analyze the location of the SNP (e.g. 5'-upstream, 3'-untranslated regions, and intronic) and its possible functional effects, such as amino acid changes in protein structure, transcription factor binding sites in promoter or intronic enhancer regions, and alternative splicing regulation by disrupting exonic splicing enhancers (ESEs) or silencers\(^{22,23}\).

Statistical analysis

All statistical analyses in this study were performed using SPSS version 18.0 (SPSS, Chicago, IL). The Mann-Whitney U test was used for the comparison of continuous variables between control and CAD groups. For categorical variables, Chi2 or Fisher’s exact tests were performed. The association of the SNPs with CAD and restenosis after coronary stenting was performed under five inheritance models using logistic regression test. The correction of the p-values (pC) was performed using Bonferroni test. The HAPLOVIEW version 4.1 software (Cambridge, MA, USA) was used for the haplotypes construction and linkage disequilibrium analysis (LD, D\(^{2}\)). The Hardy–Weinberg equilibrium (HWE) among our study population was estimated through Chi-square test. The statistical power to detect an association with CAD was 0.80. We used the OpenEpi software [http://www.openepi.com/SampleSize/SSCC.html].
Table 1. Clinical and angiographic characteristics of the CAD patients with and without restenosis

|                          | With restenosis, n (%) | Without restenosis, n (%) | p-value |
|--------------------------|------------------------|----------------------------|---------|
| Men*                     | 51 (70)                | 119 (78)                   | NS      |
| Restenosis               | 66 (30)                | 153 (70)                   | -----   |
| Unstable angina*         | 26 (39)                | 43 (28)                    | NS      |
| Stable angina*           | 6 (9)                  | 34 (22)                    | 0.017   |
| Statin therapy*          | 53 (80)                | 131 (86)                   | NS      |
| DES*                     | 18 (27)                | 94 (61)                    | <0.001  |
| BSM*                     | 48 (73)                | 58 (39)                    | <0.001  |
| Diameter smaller*        | 20 (30)                | 30 (20)                    | 0.04    |
| 2.5 mm                   |                        |                            |         |
| Stent length* (mm)       | 39 (59)                | 85 (56)                    | NS      |
| Age* (years)             | 60.4 (54-67)           | 59.1 (53-65)               | NS      |

*% n (%): number and proportion of subjects with the clinical and angiographic characteristic in both groups. BMS: bare-metal stent; DES: drug-eluting stent.

Results

Characteristics of the study population

The angiographic characteristics of the patients with and without restenosis are presented on Table 1. The patients who underwent coronary bare-metal stent implantation develop more restenosis (73%) than those of the patients who underwent drug-eluting stent implantation (27%) (p ≤ 0.001). In addition, the presence of the stable angina (9%) as well as the diameter ≤ 2.5 mm (20%) was minor in patients with restenosis than without restenosis. On the other hand, when we analyzed the demographic characteristics and biochemical parameters as CAD patients and healthy controls, there are significant differences between patients with CAD and healthy controls. The “AG” haplotype was associated with high risk of developing restenosis (OR = 1.28, 95% CI: 1.02-1.62, p = 0.031). In this study, we did not find any other haplotype associated because these SNPs are in strong evidence of recombination (D’ = 0.47), which results in that not joint cosegregation of these polymorphisms in the cases and controls.

Allele and genotype frequencies

Genotype frequencies in the polymorphic sites were in HWE. In a first analysis, the allele and genotype frequencies of the CETP polymorphisms were similar in patients with and without restenosis (data no shown). However, the analysis made comparing the whole group of patients (with or without restenosis) and healthy controls showed that under dominant model, the carriers of G allele of the CETP Taq1B A5454-G polymorphism increased risk of developing CAD when compared to carriers of the A allele (odds ratio [OR] = 1.48, 95% CI: 1.03-2.14, pC_Dom = 0.032). Also under codominant, dominant, and additive models, the carriers of A allele of the CETP −971 A/G polymorphism were associated with increased risk of developing CAD when compared to carriers of the G allele (OR = 2.03, 95% CI: 1.20-3.43, pC_Co-dom = 0.022, OR = 1.83, 95% CI: 1.15-2.89, pC_Dom = 0.008, and OR = 1.39, 95% CI: 1.08-1.79, pC_Add = 0.011, respectively) (Table 3). All models were adjusted by gender, age, body index mass (BMI), glucose, total cholesterol, HDL-C, LDL cholesterol, triglycerides, hypertension, T2DM, dyslipidemia, and smoking habit.

Linkage disequilibrium analysis

The linkage disequilibrium analysis between the Taq1B A/G and −971 A/G polymorphisms SNPs located in the CETP gene showed four common haplotypes (Table 4). One of them four showed significant differences between patients with CAD and healthy controls. The “AG” haplotype was associated with high risk of developing restenosis (OR = 1.28, 95% CI: 1.02-1.62, p = 0.031). In this study, we did not find any other haplotype associated because these SNPs are in strong evidence of recombination (D’ = 0.47), which results in that not joint cosegregation of these polymorphisms in the cases and controls.

Functional prediction

According, with the in silico programs ESEfinder 3.0 and SNP function prediction, the functional prediction analysis showed that the presence of the G allele of the Taq1B A/G polymorphism produces a binding motif for the MAF transcription factor. The analysis also revealed that the A allele of the −971 A/G polymorphism generates binding motifs for SP3 transcription factor. This analysis suggests that Taq1B A/G and −971 A/G SNPs located in the CETP gene could be influence in the expression other molecules.

Discussion

In our study, we found that the G and A alleles of the Taq1B A/G and −971 A/G SNPs, respectively, were
### Table 2. Baseline clinical characteristics of the studied individuals (patients with CAD and healthy controls)

| Clinical characteristics | CAD patients (n [%]) (n = 219) | Healthy controls (n [%]) (n = 607) | p-value |
|--------------------------|-------------------------------|-----------------------------------|---------|
| Age (years)              | 59 [54-66]                    | 53 [48-59]                        | <0.0001 |
| BMI (kg/m²)              | 26 [24.2-29.1]                | 28 [25.5-30.7]                    | <0.0001 |
| Blood pressure (mmHg)    |                               |                                   |         |
| Systolic                 | 120 [110-135]                 | 115 [107-127]                     | <0.0001 |
| Diastolic                | 80 [70-80]                    | 72 [67-78]                        | <0.0001 |
| Glucose (mg/dl)          | 117 [94-159]                  | 91 [84-98]                        | <0.0001 |
| Total cholesterol (mg/dl)|                               |                                   |         |
|                         | 161 [130-196]                 | 189 [165-209]                     | <0.0001 |
| HDL-C (mg/dl)            | 40 [34-49]                    | 42 [35-53]                        | 0.077   |
| LDL-C (mg/dl)            | 102 [70-135]                  | 115 [95-134]                      | 0.001   |
| Triglycerides (mg/dl)    | 167 [120-212]                 | 154 [113-210]                     | 0.144   |
| Gender, n (%)            |                               |                                   |         |
| Male                     | 170 (78)                      | 461 (76)                          | 0.344   |
| Female                   | 49 (22)                       | 146 (24)                          |         |
| Hypertension, n (%)      | Yes                           | 98 (45)                           | 0.092   |
| Type II diabetes mellitus, n (%) | Yes | 105 (48) | 55 (9) | <0.0001 |
| Dyslipidemia, n (%)      | Yes                           | 176 (80)                          | 0.087   |
| Smoking, n (%)           | Yes                           | 134 (61)                          | <0.0001 |

Data are expressed as median and percentiles (25th-75th). p values were estimated using Mann–Whitney U-test continuous variables and Chi-square test for categorical values.

### Table 3. Distribution of CETP polymorphisms in patients with CAD and healthy controls

| Genotype frequency | Allele frequency | Model          | OR (95% CI)       | pC   |
|--------------------|------------------|----------------|-------------------|------|
| **CETP Taq1B**     |                  |                |                   |      |
| Control            | AA               | AG             | GG                | A/G  |
| (n = 604)          | 187 (0.309)      | 285 (0.471)    | 132 (0.218)       | 0.546/0.454 |
|                    | Codominant       | Dominant       |                   |      |
|                    | 1.56 (0.99-2.13) | 1.48 (1.03-2.14) |                  | 0.093 |
|                    | Recessive        | Overdominant   |                   | 0.032 |
| CAD                | 52 (0.241)       | 109 (0.504)    | 55 (0.261)        | 0.493/0.507 |
| (n = 216)          |                  |                |                   |      |
|                    | 1.23 (0.85-1.78) | 1.18 (0.86-1.62) |                  | 0.281 |
|                    | Log-additive     |                |                   | 0.310 |
| **CETP -971 A/G**  |                  |                |                   |      |
| Control            | GG               | AG             | AA                | A/G  |
| (n = 604)          | 138 (0.229)      | 310 (0.513)    | 156 (0.257)       | 0.514/0.486 |
|                    | Codominant       | Dominant       |                   |      |
|                    | 2.03 (1.20-3.43) | 1.83 (1.15-2.89) |                  | 0.022 |
|                    | Recessive        | Overdominant   |                   | 0.008 |
| CAD                | 35 (0.161)       | 118 (0.541)    | 65 (0.298)        | 0.571/0.429 |
| (n = 218)          |                  |                |                   |      |
|                    | 1.43 (0.92-1.92) | 1.14 (0.80-1.61) |                  | 0.468 |
|                    | Log-additive     |                |                   | 0.121 |

The p-values were calculated by the logistic regression analysis, and ORs were adjusted for age, gender, blood pressure, BMI, glucose, total cholesterol, HDL-C, LDL-C, triglycerides, and smoking habit. CAD: coronary artery disease; OR: odds ratio; CI: confidence interval; pC: p-value.
associated with an increased risk of developing CAD, but not with restenosis after coronary stenting. As far as we know, our work is one of few studies that describe the association of the Taq1B A/G and −971 A/G SNPs with risk of developing restenosis. In the literature, the association of these polymorphisms with restenosis is controversial with positive and negative results. For example, in contrast with our results, Kaestner et al. reported that Taq1B A/G SNP not is associated with restenosis after coronary stenting24. In line with this data, Zee et al. reported that Taq1B A/G SNP not is associated with incidence of restenosis after PTCA25. Nonetheless, it has been shown that the G allele of the Taq1B A/G SNP increased the risk of developing cardiovascular diseases such as CAD, acute coronary syndrome (ACS), and myocardial infarction14-16,26. In addition, the analysis of the −971 A/G SNP showed that the A allele increased risk of developing CAD in our population. In contrast with these data, Wang et al., in a meta-analysis, reported that the −971 A/G SNP not is associated with myocardial infarction in Caucasian and Asian populations14. Nonetheless, the haplotype analysis showed that the “AG” haplotype confounded by −971 A/G, and Taq1B A/G SNPs increased the risk of developing restenosis, similarly to previous report15. In this context, the haplotype has −971 A and Taq1B G alleles, and both of them were associated independently with the disease. This finding corroborated the role of these two alleles in the genetic susceptibility to CAD whether they were analyzed independently or as haplotypes. Finally, in our study, the −971 A/G and Taq1B A/G polymorphisms were associated with the risk of developing CAD, but controversial with other population. We suggest that the association of these SNPs may be due cardiovascular risk factors that play an important role in the development of the CAD27, as well as, to the ethnic origin of the study populations. In this context, our population presents a characteristic genetic background that differs from other populations28-30. Therefore, we considered that more studies with a greater number of individuals and with different ethnic origins are needed to explain the true role of CETP SNPs in the risk of developing CAD.

Moreover, using bioinformatics tools, we determined the potential effect of the polymorphisms associated with the developing of restenosis. The analysis of the Taq1B A/G polymorphism showed that the presence of the G allele produces a binding motif for the MAF transcription factor. The MAF transcription factor is a basic region leucine zipper (bZIP)-type that is essential for activation or repression of pro-inflammatory cytokines in T cells, NKT cells, and regulatory T cells that play an important role in the inflammatory process31,32. On the other hand, the analysis of the −971 A/G polymorphism also revealed that the A allele generates binding motifs for SP3 transcription factor. SP3 transcription factor regulates the expression of tumor necrosis factor-alpha pathway inhibitors of apoptosis proteins and nuclear factor kB33. In addition, the SP3 transcription factor regulates CETP promoter activity and thus contributes significantly to variation in plasma CETP mass concentration34,35. Additional to this information, experimental studies have shown that Taq1B A/G and −971 A/G polymorphisms are associated with the CETP activity, and concentration of HDL-C levels32,35. However, in contrast with these data, He et al., in a meta-analysis study, reported that the serum HDL-C levels are not associated with in-stent restenosis or CAD36. Nonetheless, data in the literature proposed that the role of CETP SNPs may be more important on the HDL structure that rather of the HDL-C plasma levels; due the selective increase.

### Table 4. Frequencies (%) of haplotypes of the CETP −971 A/G and CETP Taq1B A/G polymorphisms in patients with CAD and healthy controls

| −971 A/G | Taq1B A/G | CAD | Controls | OR | 95% CI | pC |
|----------|-----------|-----|----------|----|--------|----|
| Haplotype | Hf | Hf |
| G        | A         | 0.290 | 0.340 | 0.79 | 0.62-1.01 | 0.062 |
| A        | G         | 0.365 | 0.310 | 1.28 | 1.02-1.62 | 0.031 |
| A        | A         | 0.203 | 0.205 | 0.99 | 0.75-1.30 | 0.961 |
| G        | G         | 0.142 | 0.145 | 0.96 | 0.70-1.32 | 0.831 |

The order of the polymorphisms in the haplotypes is according to the positions in the chromosome [CETP −971 A/G (rs4783961) and CETP Taq1B A/G (rs708272)]. Hf: haplotype frequency; CAD: coronary artery disease; pC: p-corrected.
or decrease of cholesterol associated to certain HDL subclasses, probably the result of an impaired metabolism of lipoproteins\(^9,^{37,38}\). However, the precise mechanism by which CETP participates in the concentration and remodeling of HDL-C remains to be elucidated. Nonetheless, we think that future investigations are warranted to understand the contribution of these polymorphisms to HDLs metabolism.

**Conclusion**

We found that the \textit{Taq1B A/G} and \textit{−971 A/G} polymorphisms of the \textit{CETP} gene are associated with an increased risk of developing CAD, but not with restenosis after coronary stenting. On the other hand, due to the number of individuals included in our study and the specific genetics characteristics of the Mexican population, we considered that additional studies in a larger number of individuals and in other populations could help to define the true role of these polymorphisms as marker risk or protection in the developing restenosis after coronary stenting.

**Acknowledgments**

The authors are grateful to the study participants. Institutional Review Board approval was obtained for all sample collections. The authors are grateful to the technicians Marva Arellano-Gonzalez and Silvestre Ramirez-Fuentes for their participation in the collection of samples and extraction of DNA.

**Funding**

This research was funded by Consejo Nacional de Ciencia y Tecnología (CONACYT), Mexico City, Mexico (Project \textit{Fronteras de la Ciencia-1958}).

**Conflicts of interest**

The authors have declared that no competing interests exist.

**Ethical disclosures**

**Protection of human and animal subjects.** The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

**Confidentiality of data.** The authors declare that they have followed the protocols of their work center on the publication of patient data.

**Right to privacy and informed consent.** The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

**References**

1. Latib A, Musardo M, Ielasi A, Tania G, Godino C, Al-Lamee R, et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. JACC Cardiovasc Interv. 2011;4:155-64.
2. Miranda-Malpica E, Martinez-Rios MA, Fragoso JM, Delgadillo-Rodriguez H, Rodriguez-Perez JM, Gonzalez-Quezada C, et al. The interleukin 1B-511 polymorphism is associated with the risk of developing restenosis after coronary stenting in Mexican patients. Hum Immunol. 2008;69:116-21.
3. Palomo Villada JA, Bernal E, Santiago J, Abundes Velasco A, Montoya Silvestre A, Flores Flores J, et al. Clinical restenosis in diabetic patients treated with drug eluting stents for de novo lesions. Arch Cardiol Mex. 2007;77:110-9.
4. Martinez- Rios MA, Mendez-Ortiz A, Gaspar J, Barragan-Garcia R, Fernandez de la Reguera G, Gonzalez-Quezada C.J. Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in patient with cardiac allograft vasculopathy. Arch Cardiol Mex. 2008;78:407-12.
5. Johansson SR, Wiklund O, Karlsson T, Hjalmarsen A, Emanuelsson H. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. Eur Heart J. 1991;12:1020-8.
6. Shah PK, Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation. 1992;85:1279-85.
7. Li Y, Jin P, Hou F, Zhuo Y. Association between TG-to-HDL-C ratio and in-stent stenosis under optical coherence tomography guidance. J Med Syst. 2019;43:4.
8. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161:245-54.
9. Perez-Mendez O, Pacheco HG, Martinez-Sanchez C, Franco M. HDL-cholesterol in coronary artery disease risk: function or structure? Clin Chim Acta. 2014;429:111-22.
10. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol ester transfer protein and lecithin cholesterol acyl transferase. Arterioscler Thromb Vasc Biol. 1997;17:56-63.
11. Khera AV, Cuchel M, de la Llera-Moya M, Rodriguez A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.
12. Ordovas JM, Cupples A, Corella D, Otvos JD, Osogo D, Martinez A, et al. Association of cholesterol ester transfer protein-Taq1B polymorphism with variations in lipoprotein subclasses and coronary artery disease risk The Framingham Study. Arterioscler Thromb Vasc Biol. 2000;20:1329-9.
13. Lu Y, Tayebi N, Li H, Saha N, Yang H, Heng CK. Association of CETP Taq1B and -629 C>A polymorphisms with coronary artery disease and lipid levels in the multi-ethnic Singaporean population. Lipids Health Dis. 2013;12:85.
14. Wang Q, Zhou SB, Wang LJ, Lei MM, Wang Y, Mao C, et al. Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regression. PLoS One. 2014;9:e88118.
15. Guo SX, Yao MH, Ding YS, Zhang JY, Yan YZ, Liu JM, et al. Associations of cholesterol ester transfer protein Taq1B polymorphism with the composite ischemic cardiovascular disease risk and HDL-C concentrations; a meta-analysis. Irj J Environ Res Public Health. 2016;13:882.
16. Meiner V, Friedlander Y, Milo H, Sharon N, Ben-Avi L, Shpitzin S, et al. Cholesterol ester transfer protein (CETP) genetic variation and early onset of non-fatal myocardial infarction. Ann Hum Genet. 2008;72:732-41.
17. Posadas-Sanchez R, Perez-Hernandez N, Angeles-Martinez J, Lopez-Bautista F, Villareal-Molina T, Rodriguez-Perez JM, et al. Interleukin 35 polymorphisms are associated with decreased risk of premature coronary artery disease, metabolic parameters, and IL-35 levels: the genetics of atherosclerotic disease (GEA) study. Med Inflamm. 2017;2017:2012795.
G. Vargas-Alarcon et al.: CETP gene SNPs are associated with CAD

18. DeLong DM, DeLong ER, Wood PD, Lippel K, Ritkind BM. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

19. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.

20. Schaid DJ. Disease-marker association. In: Elston RC, Olson JM, Palmer L, editors. Biostatistical Genetics and Genetic Epidemiology. Chichester: Wiley; 2002. p. 216-7.

21. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

22. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.

23. Schaid DJ, Disease-marker association. In: Elston RC, Olson JM, Palmer L, editors. Biostatistical Genetics and Genetic Epidemiology. Chichester: Wiley; 2002. p. 216-7.

24. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

25. Schaid DJ, Disease-marker association. In: Elston RC, Olson JM, Palmer L, editors. Biostatistical Genetics and Genetic Epidemiology. Chichester: Wiley; 2002. p. 216-7.

26. Schaid DJ, Disease-marker association. In: Elston RC, Olson JM, Palmer L, editors. Biostatistical Genetics and Genetic Epidemiology. Chichester: Wiley; 2002. p. 216-7.

27. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

28. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

29. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

30. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

31. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

32. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

33. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

34. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

35. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

36. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

37. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.

38. Clayton D, Lander ES. A comparison of methods for the estimation of plasma low-and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA. 1986;256:2372-7.